TOXICOLOGY/SAFETY STUDIES OF A CHRONIC PAIN THERAPEUTIC

申请者描述：该项目建议开发一种新工具 用于这项研究，并可能用于慢性疼痛的治疗。同相 I，P物质和核糖体之间的一种有效和特定的偶联物- 产生失活蛋白皂苷。在第二阶段，这种试剂 将通过使其同质化、更具体、更活跃来进行优化 更便于客户使用。新优化的试剂将是 与第一阶段使用的试剂相比，消除NK-1的能力 在脊髓的后角，有受体神经元。数据 与新结构的聚集可能表明P物质毒素 在治疗疼痛方面是有用的。SP-SAP在以下方面的成功 Vivo已经表示，其他多肽毒素可以商业化。在……里面 为了更全面地解决有关疼痛传递的问题，它是 建议在莫阿片类药物德吗啡之间制造一种偶联物 受体特异性激动剂和皂苷，以进一步描绘 疼痛传递的途径。这一组合也将引起广泛的兴趣 一组研究人员。 建议的商业应用： 这些产品作为工具存在着一个小而热情的市场 神经科学界的基础研究人员。申请者提供 对成本和市场规模的详细估计。申请组织 目前市场上有一种用于消融乙酰胆碱的皂素结合物 包含单元格。目前还没有竞争对手的产品。因此， 申请组织似乎已经做好了开发该产品的准备。那里 有充分的理由相信第二阶段的实验将提供 为更高效地生产更多靶向毒素奠定基础 这将增加该公司的产品线。

APPLICANT'S DESCRIPTION: This project proposes development of a new tool for the research and potentially the treatment of chronic pain. In Phase I, a potent and specific conjugate between substance P and the ribosome- inactivating protein saponin was produced. In Phase II, this reagent will be optimized by making it homogeneous, more specific, more active and easier for the customer to use. The newly optimized reagent will be compared to the reagent used in Phase I for ability to eliminate NK-1 receptor-bearing neurons, in the dorsal horn of the spinal cord. Data gathered with the new construct may indicate that the substance P toxin is therapeutically useful in pain management. The success of SP-SAP in vivo has indicated that other peptide-toxins can be commercialized. In order to more fully address questions about pain transmission, it is proposed to produce a conjugate between dermorphin, a mu opioid receptor-specific agonist, and saponin in order to further delineate the pathway of pain transmission. This conjugate will also interest a broad group of researchers. PROPOSED COMMERCIAL APPLICATION: A small but enthusiastic market exists for these products as tools for basic researchers in the neuroscience community. The applicant provides a detailed estimate of cost and market size. The applicant organization currently markets a saponin conjugate for ablation of acetylcholine containing cells. There are currently no competing products. Thus, the applicant organization appears well poised to exploit the product. There is good reason to believe that the Phase II experiments will provide a foundation for more efficient production of additional targeted toxins that will add to the company's product line.